



204 Executive Court
Little Rock, AR 72205
501-444-2385

[WEBSITE](#)

OVERVIEW OF MESENCHYMAL STEM CELL THERAPY FOR HIP ARTHRITIS AND HIP DEGENERATION

Mesenchymal stem cell (MSC) therapy represents a promising regenerative approach for treating hip osteoarthritis (OA), a degenerative condition characterized by cartilage breakdown, pain, stiffness, and reduced mobility in the hip joint. MSCs, typically derived from bone marrow, adipose tissue, or umbilical cord, possess anti-inflammatory, immunomodulatory, and tissue-regenerative properties. **They can differentiate into cartilage-like cells (chondrocytes) and secrete bioactive factors that may reduce inflammation, inhibit cartilage degradation, and promote repair.** This therapy is particularly appealing for early-to-moderate-stage hip OA (e.g., Tönnis grades 0–2), where conservative treatments like NSAIDs, physical therapy, or corticosteroid injections fail, and before advanced options like total hip arthroplasty are needed.

Usage: MSCs are administered either systemically via intravenous (IV) infusion or locally via intra-articular injection into the hip joint. IV infusion allows MSCs to circulate and home to inflamed sites, potentially providing broader anti-inflammatory effects suitable for multifocal or systemic arthritis. However, for **localized hip OA, intra-articular injection is more common, delivering cells directly to the joint under imaging guidance (e.g., fluoroscopy or ultrasound) to target cartilage defects.** Doses typically range from 20–100 million cells, often autologous (patient-derived) to minimize rejection, though allogeneic sources are explored. Procedures are minimally invasive, outpatient-based, with follow-up involving pain scales (e.g., VAS, WOMAC), functional assessments (e.g., Harris Hip Score), and imaging (MRI, X-ray) to monitor outcomes.

OBSERVATIONAL RESEARCH ON AN EXPERIMENTAL USE PARADIGM

Testing: Preclinical animal models (e.g., rats, rabbits) demonstrate MSC efficacy in reducing OA progression via paracrine effects and cartilage regeneration. Human studies, mostly small Phase I/II trials or case series (n=10–50 patients), report safety with no major adverse events (e.g., infection, embolism) and benefits like pain reduction (20–50% improvement) and functional gains lasting 6–60 months. However, evidence is limited by small sample sizes, lack of randomization, short follow-ups, and variable MSC preparation (e.g., expansion, dosing). Systematic reviews highlight positive trends but call for larger randomized controlled trials (RCTs) to confirm disease-modifying effects, as radiological improvements (e.g., cartilage volume) are inconsistent. IV delivery is less studied for hip OA specifically, with most data on knee OA or rheumatoid arthritis (RA), showing systemic immune modulation but uncertain joint-specific benefits.

Below, I list 5 scientific papers each on the potential benefits of IV infusion and intra-articular injection for MSC therapy in hip OA (or closely related OA contexts where hip-specific data is sparse). These focus on clinical outcomes like pain relief, functional improvement, and safety. For IV, research is limited for hip OA alone, as systemic delivery is often tested in broader OA or inflammatory arthritis; I've prioritized relevant studies emphasizing benefits. Each entry includes a link to the paper and a brief summary.

These studies highlight systemic anti-inflammatory effects, pain reduction, and symptom improvement, with potential applicability to hip OA through reduced joint inflammation and immune modulation.

Mesenchymal Stem Cell Therapy via IV Infusion for Hip Arthritis

5 Papers on Potential Benefits of MSCs Delivered by IV Infusion. These studies highlight systemic anti-inflammatory effects, pain reduction, and symptom improvement, with potential applicability to hip OA through reduced joint inflammation and immune modulation.

Park EH et al. (2018). **Intravenous Infusion of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase Ia Clinical Trial.** Stem Cells Transl Med.

Link: <https://pmc.ncbi.nlm.nih.gov/articles/PMC6127229/>

Brief summary: This Phase Ia trial in 9 RA patients showed IV infusion of umbilical cord blood-derived MSCs was safe, with reduced joint pain, inflammatory markers (e.g., CRP,

Copyright © 2025 MDVISIT rights reserved. Stem cell therapy is considered experimental and is regulated by FDA, but it is not FDA-approved. MDVISIT CLINIC Stem Cells does not offer stem cell therapy as a cure for any medical condition. No statements made on this site have been evaluated or approved by the FDA. This site does not provide medical advice and all therapy is provided as OBSERVATIONAL RESEARCH ON AN EXPERIMENTAL USE PARADIGM. All content is for informational purposes only and is not a substitute for professional medical consultation, diagnosis, or treatment. MDVISIT CLINIC Stem Cell is not responsible for the outcome of your procedure. The FDA considers stem cell therapy experimental at this point.

OBSERVATIONAL RESEARCH ON AN EXPERIMENTAL USE PARADIGM

ESR), and DAS28 scores over 6 months, suggesting immunomodulatory benefits for inflammatory arthritis.

Barmada A et al. (2023). **Review of the Published Literature Confirms the Safety of Intravenous Infusion of Mesenchymal Stem Cells.** *Curr Stem Cell Res Ther.*

Link: <https://pubmed.ncbi.nlm.nih.gov/36043768/>

Brief summary: A systematic review of 70 studies (thousands of IV MSC infusions) confirmed high safety with near absence of serious adverse events, including reduced inflammation and pain in OA/RA cases, supporting IV delivery for joint diseases.

Wang D et al. (2022). **Efficacy and Safety of Mesenchymal Stem Cell Therapy in Patients with Acute Myocardial Infarction: A Systematic Review and Meta-analysis of Randomized Controlled Trials.** *Curr Stem Cell Res Ther.*

Link: <https://pubmed.ncbi.nlm.nih.gov/34397334/>

Brief summary: Meta-analysis of RCTs showed IV MSCs improved function and reduced inflammation in cardiac patients, with parallels to OA via cytokine modulation (e.g., IL-6, TNF- α), highlighting systemic benefits for inflammatory conditions like arthritis.

Liang J et al. (2010). **Allogeneic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study.** *Ann Rheum Dis.*

Link: <https://pubmed.ncbi.nlm.nih.gov/20650877/>

Brief summary: IV allogeneic MSCs in 4 refractory SLE patients led to remission, reduced autoantibodies, and joint symptom improvement, indicating immunomodulatory potential for arthritic conditions with no major adverse events.

Álvarez-Gracia JM et al. (2017). **Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611):** results of a multicenter, dose escalation, randomized, single-blind, placebo-controlled phase Ib/IIa clinical trial. *Ann Rheum Dis.*

Link: <https://pubmed.ncbi.nlm.nih.gov/27269294/>

OBSERVATIONAL RESEARCH ON AN EXPERIMENTAL USE PARADIGM

Brief summary: RCT in 53 refractory RA patients showed IV adipose-derived MSCs reduced pain, improved quality of life, and were safe, with implications for OA via shared inflammatory pathways.

Mesenchymal Stem Cell Therapy via Intra-Articular Injection into the Hip

Note: Intra-articular MSC injection is a common method for delivering cells directly into the hip joint for localized OA treatment. It has been tested in human studies, showing benefits like pain reduction and functional improvement. Below are 5 papers on this approach for hip OA.

1. ****Title:** Mesenchymal Stem Cells injection in hip osteoarthritis: preliminary results**

****Authors:**** Carlo Dall'Oca et al.

****Publication Date:**** January 10, 2019

****Link:**** <https://pubmed.ncbi.nlm.nih.gov/30715002/>

****Review:**** In 6 patients with mild hip OA (Tönnis grades 0-2) resistant to conservative care, intra-articular injection of autologous adipose-derived MSCs improved Harris Hip Score from 67.2 to 84.6 and reduced WOMAC score from 36.3 to 19.8 at 6 months. No adverse effects occurred. Results show functional gains and pain relief. Benefits include safety, ease of technique, and positive outcomes in pain/function, though longer follow-up is needed.

2. ****Title:** Mesenchymal stem cell therapy in the treatment of hip osteoarthritis**

****Authors:**** Rodrigo Mardones et al.

****Publication Date:**** March 19, 2017

****Link:**** <https://pubmed.ncbi.nlm.nih.gov/28630737/>

****Review:**** Ten patients with hip cartilage defects received three weekly intra-articular infusions of 60×10^6 autologous bone marrow-derived MSCs. Hip scores for pain, stiffness, and function improved, with stable Tönnis radiographic scores in 9/10 patients. Results confirm safety and efficacy in restoring function/range of motion. Benefits include joint preservation and clinical improvement without progression in most cases.

Copyright © 2025 MDVISIT rights reserved. Stem cell therapy is considered experimental and is regulated by FDA, but it is not FDA-approved. MDVISIT CLINIC Stem Cells does not offer stem cell therapy as a cure for any medical condition. No statements made on this site have been evaluated or approved by the FDA. This site does not provide medical advice and all therapy is provided as OBSERVATIONAL RESEARCH ON AN EXPERIMENTAL USE PARADIGM. All content is for informational purposes only and is not a substitute for professional medical consultation, diagnosis, or treatment. MDVISIT CLINIC Stem Cell is not responsible for the outcome of your procedure. The FDA considers stem cell therapy experimental at this point.

OBSERVATIONAL RESEARCH ON AN EXPERIMENTAL USE PARADIGM

3. **Title:** **The Efficacy of Bone Marrow Stem Cell Therapy in Hip Osteoarthritis: A Scoping Review**

Authors: Olivia F Perez et al.

Publication Date: June 7, 2024

Link: <https://pubmed.ncbi.nlm.nih.gov/39564400/>

Review: Reviewing 7 studies (72 patients), intra-articular bone marrow MSC injections **reduced pain (numerical/visual analogue scales) and improved function** (Western Ontario and McMaster Universities Osteoarthritis Index). All used low doses; no clear dose-response due to variable follow-up. Results show consistent clinical benefits. Benefits include pain relief and functional gains, with calls for high-dose/long-term studies.

4. **Title:** **Short-Term Outcomes of Treatment of Hip Osteoarthritis With 4 Bone Marrow Concentrate Injections: A Case Series**

Authors: Marc Darrow et al.

Publication Date: August 10, 2018

Link: <https://pubmed.ncbi.nlm.nih.gov/30116104/>

Review: **Four hip OA patients received 4 intra-articular bone marrow concentrate injections, showing 72.4% overall improvement**, reduced resting/active pain, and less daily activity difficulty at 3.5 months average follow-up. Results support short-term symptom relief. Benefits include quality-of-life gains and pain reduction as a joint replacement alternative, warranting further research.

5. **Title:** **Clinical use of autologous adipose-derived stromal vascular fraction cell injections for hip osteoarthritis**

Authors: Yuma Onoi et al.

Publication Date: June 15, 2023

Link: <https://pubmed.ncbi.nlm.nih.gov/37363753/>

OBSERVATIONAL RESEARCH ON AN EXPERIMENTAL USE PARADIGM

****Review:**** Forty-two patients (Kellgren-Lawrence grades II-IV) received a single intra-articular injection of $\sim 3.8 \times 10^7$ adipose-derived SVF cells. **Harris Hip Score improved from 22.5 to 46.8, Japanese Orthopedic Association Hip Disease Evaluation Questionnaire from 26.6 to 39.4, and visual analogue scale from 75.5 to 46.5 at 6 months. Greater benefits in milder grades;** no radiographic changes. Results show short-term efficacy. Benefits include symptom reduction, safety, and ease of harvest compared to traditional MSCs.